Who
Robert E. Landry
Director
Company insider
Files Form 4 as: Director, Cytokinetics; Director, Zymeworks; EVP Finance CFO, Regeneron Pharmaceuticals.
In numbers
- Trades disclosed
- 536
- Buys
- 0
- Sells
- 48
- Bought
- $0
- Sold
- $23.5M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 9 Sep 2013
- Last trade
- 15 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 15 Sep 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $72K1,000 at $72.13 | filing |
| 15 Sep 2026filed 15 Sep 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $72K1,000 at $72.13 | filing |
| 11 Sep 2026filed 11 Sep 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $75K1,000 at $74.66 | filing |
| 11 Sep 2026filed 11 Sep 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $75K1,000 at $74.66 | filing |
| 27 May 2026filed 27 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —2,851 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,301 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,301 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —2,851 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,500 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,700 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,500 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,700 at $0.00 | filing |
| 11 Aug 2025filed 12 Aug 2025 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,000 at $0.00 | filing |
| 14 May 2025filed 14 May 2025 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,880 at $0.00 | filing |
| 14 May 2025filed 14 May 2025 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —7,333 at $0.00 | filing |
| 10 Feb 2025filed 11 Feb 2025 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,538 at $0.00 | filing |
| 2 Feb 2024filed 6 Feb 2024 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —400 at $0.00 | filing |
| 2 Feb 2024filed 6 Feb 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $152K400 at $378.98 | filing |
| 2 Feb 2024filed 6 Feb 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $269K281 at $956.65 | filing |
| 31 Jan 2024filed 2 Feb 2024 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —400 at $0.00 | filing |
News
Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Cytokinetics (NASDAQ:CYTK)CYTK · themarketsdaily.com · 25 Oct 2026Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) vs. Cytokinetics (NASDAQ:CYTK)CYTK · dailypolitical.com · 18 Oct 2026Contrasting Gain Therapeutics (NASDAQ:GANX) and Cytokinetics (NASDAQ:CYTK)CYTK · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Robert E. Landry; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.